Xueyuan GUO

Dr. Xueyuan GUO


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2019 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
CLChang Liu
Chang Liu
XDXin Du
Xin Du
CJChao Jiang
Chao Jiang
LHLiu He
Liu He
SCSan-Shuai Chang
San-Shuai Chang
CMChangsheng Ma
Changsheng Ma
BACKGROUND:Oral anticoagulants (OACs) such as warfarin and non-VKA oral anticoagulants (NOACs) have been recommended for patients with atrial fibrillation (AF) who are at risk for stroke. Whether NOACs have a higher persistence than warfarin is still...

3 February 2026 in Circulation
Verified
Journal Article
Open access
CJChao Jiang
Chao Jiang
ZZZixu Zhao
Zixu Zhao
ZYZejun Yang
Zejun Yang
YWYiping Wang
Yiping Wang
YXYang Xu
Yang Xu
CMChangsheng Ma
Changsheng Ma
BACKGROUND: Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors. METHODS: The DARE-AF trial (Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation) was a prospective, open-label, parallel-assignment randomized controlled trial that enrolled 200 patients with persistent AF between July 2024 and March 2025, scheduled to undergo a first catheter ablation procedure and without established indications for dapagliflozin (diabetes, heart failure, or chronic kidney disease). Patients were randomly assigned at a 1:1 ratio to dapagliflozin (10 mg once daily for 3 months after the ablation) or control. The primary end point was AF burden at 3 months after ablation, assessed by 7-day single-lead ECG patches. Secondary outcomes included time to events, quality of life, and improvement of atrial remodeling. RESULTS: A total of 200 patients (mean age 58.5 years, 19.5% women, 29.0% with persistent AF ≥1 year) were randomized, and 198 patients (98 in the dapagliflozin group, 100 in the control group) were included in the primary analysis. Three months after ablation, the difference in AF burden was insignificant between the dapagliflozin group and the control group (7.5±23.6% versus 8.1±25.5%; P =0.48). Atrial arrhythmia recurrence occurred in 29 patients (29.6%) in the dapagliflozin group and 28 patients (28.0%) in the control group (hazard ratio, 1.11 [95% CI, 0.66–1.86]; P =0.70). No significant between-group differences were observed in changes in quality of life or left atrial diameter. CONCLUSIONS: Three-month treatment with dapagliflozin did not reduce the early recurrence of arrhythmia after catheter ablation in patients with persistent AF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06433479.

6 September 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XGXueyuan GUO
Xueyuan GUO
MLMengmeng Li
Mengmeng Li
XDXin Du
Xin Du
CJChenxi Jiang
Chenxi Jiang
SLSong-nan Li
Song-nan Li
CMChangsheng Ma
Changsheng Ma
Background: Multimorbidity, polypharmacy and inappropriate prescribing is common in elderly patients worldwide. We aimed to explore the current status of multimorbidity, polypharmacy and the appropriateness of pharmacological therapy among elderly patients with atrial fibrillation (AF) in China.Materials and methods: We randomly selected 500 patients aged 65 years or older from the China AF Registry study. Multimorbidity was defined as ≥2 comorbidities and polypharmacy was defined as ≥5 long-term prescribed drugs. Appropriateness of prescribing was evaluated using the Screening Tool of Older People’s Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 2. Patients’ attitudes toward polypharmacy were evaluated by the Patients’ Attitudes Towards Deprescribing (PATD) questionnaire.Results: Among the 500 patients included (mean age 75.2 ± 6.7 years, 49.0% male), 98.0% had multimorbidity and 49.4% had polypharmacy. The prevalence of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs) was 43.6% (n = 218) and 71.6% (n = 358), respectively. Traditional Chinese medicine attributed largely to PIMs. Anticoagulants were the most common PPOs. Many clinical factors increased the risk of PIMs and PPOs. However, polypharmacy increased the risk of PIMs (OR 2.70, 95%CI 1.78–4.11; p < 0.0001), but not PPOs. In addition, 73.7% patients with polypharmacy were willing to have one or more of their medications prescribed if advised by their doctor.Conclusion: Multimorbidity and polypharmacy were highly prevalent in elderly patients with AF in China. A high prevalence of inappropriate prescribing was also observed. Therefore, much more attention should be paid to the serious health problem in the elderly population.

25 March 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
NLNa Li
Na Li
QFQian Feng
Qian Feng
FYFangfang Yu
Fangfang Yu
JZJian Zhou
Jian Zhou
XGXueyuan GUO
Xueyuan GUO
Background: Growth differentiation factor‐15 (GDF‐15) is a member of the transforming growth factor β superfamily, correlated with various stimuli, including cardiovascular disease. The association between plasma GDF‐15 level and “lone” AF, that is, AF of unknown etiology (UeAF), is uncertain.Methods: All patients aged 60 years or younger. AF patients were hospitalized for primary catheter ablation. Patients with sinus rhythm admitted for other diseases during the same period were included in the control group. ELISA was used to measure plasma GDF‐15 concentrations.Results: 60 UeAF patients, 60 paroxysmal AF (PAF) patients, and 70 control patients were enrolled. The mean age was 44.6 years. In the UeAF group, no patients had traditional clinical risk factors. The plasma GDF‐15 level in the UeAF group was (1028.5 ± 180.5) pg/ml, higher than in the control group, and moderately lower than in the PAF group. In all patients, positive correlations were found between plasma GDF‐15 level and age (R = 0.210, p < 0.05), and between plasma GDF‐15 level and left atrial diameter (LAD; R = 0.338, p < 0.05; in the UeAF group: R = 0.475, p < 0.05; in the PAF group: R = 0.504, p < 0.05).Conclusions: Our study first investigated the role of GDF‐15 in UeAF. The plasma GDF‐15 level in UeAF patients was higher than in sinus rhythm patients and lower than in PAF patients. Moreover, GDF‐15 was positively correlated with age and LAD. The role of GDF‐15 in UeAF needs further study.

31 March 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
XGXueyuan GUO
Xueyuan GUO
CSCaihua Sang
Caihua Sang
RTRibo Tang
Ribo Tang
CJChenxi Jiang
Chenxi Jiang
SLSongnan Li
Songnan Li
CMChangsheng Ma
Changsheng Ma

6 December 2023 in Clinical Cardiology
Verified
Journal Article
Open access
LZLe Zhou
Le Zhou
YKYu Kong
Yu Kong
CSCaihua Sang
Caihua Sang
SXShijun Xia
Shijun Xia
CJChao Jiang
Chao Jiang
CMChangsheng Ma
Changsheng Ma
Background: Evidence was lacking for the early choice of radiofrequency ablation (RFA) among patients with early‐onset atrial fibrillation (AF).Hypothesis: This study aimed to explore whether earlier RFA was associated with better clinical outcomes among early‐onset AF patients.Methods: Patients, who were diagnosed with AF before 45 years and underwent their first RFA procedures at baseline of the China Atrial Fibrillation registry, were enrolled and divided into four diagnosis‐to‐ablation time (DAT) groups: DAT ≤ 1 year, 1 year < DAT ≤ 3 years, 3 years < DAT ≤ 6 years, and DAT > 6 years. Another group of nonablation patients, who were newly diagnosed with AF and younger than 45 years, were also included. Adjusted associations of groups with composite cardiovascular events (cardiovascular death, embolism, major hemorrhages, or cardiac rehospitalization) or recurrent AF were analyzed using Cox proportional hazards models.Results: Among 1694 patients who underwent their first RFA at enrollment, incidences of composite cardiovascular outcomes were increasing with extension of DAT (DAT ≤ 1 year: 6.1/100 person‐years, 1 year < DAT ≤ 3 years: 7.9/100 person‐years, 3 years < DAT ≤ 6 years: 7.6/100 person‐years, DAT > 6 years: 10.5/100 person‐years; p < .001). In comparison with DAT > 6 years group, the DAT ≤ 1 year group was associated with reduced risk of cardiovascular events (adjusted hazard ratio, HR [95% confidence interval, CI] = 0.64 [0.47–0.87], p = .005) and AF recurrence (adjusted HR [95% CI] = 0.70 [0.57–0.88], p = .002). Associations remained similar after stratified by AF types. Compared to nonablation group (n = 413), DAT ≤ 1year patients tended to show lower cardiovascular risk (adjusted HR [95% CI] = 0.78 [0.58–1.05], p = .099) and lower risk of recurrent AF (adjusted HR [95% CI] = 0.46 [0.38–0.55], p < .001).Conclusions: A shorter DAT was associated with a lower risk of cardiovascular events and recurrent AF for early‐onset AF patients.